仟源医药(300254)：发布2025股票激励计划 目标利润端维持高增

Group 1 - The core point of the news is the announcement of a stock incentive plan by QianYuan Pharmaceutical, which aims to grant a total of 9.15 million restricted shares, accounting for 3.68% of the company's total equity [1] - The initial grant consists of 7.95 million shares, with a reserved 1.2 million shares, targeting 171 individuals at a price of 5.60 yuan per share [1] - The incentive plan's performance targets for 2026-2027 include a profit growth rate exceeding 36%, with revenue growth rates set at no less than 8.57%, 18.02%, and 27.57% for the years 2025, 2026, and 2027 respectively [1] Group 2 - The sales of the smoking cessation drug Varenicline are accelerating, with Q1 2025 sales reaching 17.57 million yuan and a market share of 59.5%, particularly strong in urban pharmacies [2] - The company maintains a "buy" rating, projecting net profits of 91 million, 135 million, and 175 million yuan for 2025-2027, with year-on-year growth rates of 114.7%, 48.6%, and 30.3% respectively [2] - The corresponding price-to-earnings ratios (PE) for these years are projected to be 31, 21, and 16 times [2]